Federal court rejects PhRMA challenge to Medicare drug price negotiation
Summary
A federal appeals court decided that drug companies must take part in the Medicare program that negotiates drug prices. The court rejected the pharmaceutical industry’s attempt to block this program because drugmakers cannot demand to sell their medicines at prices they choose.Key Facts
- The ruling came from the U.S. Court of Appeals for the Fifth Circuit.
- The case involved drug company representatives challenging Medicare’s drug price negotiation program.
- The court said drugmakers are not allowed to set their own prices for Medicare.
- The decision supports a program aimed at lowering drug costs for Medicare recipients.
- This ruling upholds a previous court decision.
- Medicare is a federal program that helps pay for health care for older adults and some disabled people.
- The drug price negotiation program lets Medicare negotiate lower prices for medicines.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
